Immunotherapy: Recurrent and/or metastatic head and neck cancer portends a poor prognosis with traditional treatments, but current immunotherapy with immune checkpoint inhibitors has the potential to improve these clinical outcomes. This review focuses on the major breakthroughs that have led to the current understanding of immunotherapy in head and neck cancer as well as the future direction of the field. Ultimately, this understanding will guide clinicians on the selection of patients with head and neck cancer and practical considerations before starting immunotherapy.
http://ift.tt/2uzxiwD
Ιατρική : Τα αισθητικά συστήματα της όρασης,ακοής,αφής,γεύσης και όσφρησης.
Πέμπτη 27 Ιουλίου 2017
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Head and neck squamous cell carcinoma (HNC) is one of the most common malignancies encountered in India. This is mainly attributed to rampan...
-
Abstract Median sternotomy is frequently selected for the resection of pulmonary artery tumor, and pneumonectomy is performed for complete ...
-
Publication date: Available online 26 April 2017 Source: The Journal of Prosthetic Dentistry Author(s): Prajna P. Shetty, Ramesh Chowdhar...
-
Purpose This study tested the feasibility of a method designed to assess children's sensitivity to tense/agreement information in front...
-
Primary Ewing's sarcoma of the sinonasal tract in adults: A challenging disease. Head Neck. 2016 Nov 29;: Authors: Lombardi D, Ma...
-
IGF-1R inhibition sensitizes breast cancer cells to ATM-Related Kinase (ATR) inhibitor and cisplatin. Oncotarget. 2016 Jul 27; Author...
-
Zusammenfassung Hintergrund Leiomyome des Ösophagus sind seltene Tumoren, jedoch die häufigsten gutartigen Tumoren des Ösophagus ausgehe...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου